Chronic Lymphocytic LeukemiaReal-World DataCovalent BTK inhibitorvenetoclaxAbstractToby A. Eyretoby.eyre@ouh.nhs.ukView further author informationLisa M. HessView further author informationTomoko SugiharaView further author informationDan HeView further author information...
In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting. However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated de
chronic myeloid leukemia or acute lymphocytic leukemia with 127 Yong A, Szydlo RM, Goldman JM, Apperley JF, Melo JV. the T315I BCR-ABL mutation. Blood 2007; 109: 500–502. Molecular profiling of CD34+ cells identifies low expression of 148 Paquette RL, Shah NP, Sawyers CL, Martinelli G,...